Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Treatment Phase	STARTED	Lorlatinib	149
Treatment Phase	STARTED	Crizotinib	147
Treatment Phase	COMPLETED	Lorlatinib	26
Treatment Phase	COMPLETED	Crizotinib	83
Treatment Phase	NOT COMPLETED	Lorlatinib	123
Treatment Phase	NOT COMPLETED	Crizotinib	64
Long-Term Follow-up Phase	STARTED	Lorlatinib	149
Long-Term Follow-up Phase	STARTED	Crizotinib	147
Long-Term Follow-up Phase	COMPLETED	Lorlatinib	0
Long-Term Follow-up Phase	COMPLETED	Crizotinib	0
Long-Term Follow-up Phase	NOT COMPLETED	Lorlatinib	149
Long-Term Follow-up Phase	NOT COMPLETED	Crizotinib	147

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03052608/flow